Reviewed by MedNext Clinical Team
Adverse drug reactions (ADRs) are estimated to cause approximately 5–7% of all hospital admissions in developed countries and are responsible for significant patient morbidity and mortality [1]. Yet the systematic detection of ADRs in the post-marketing period depends critically on clinician reporting — a process that is widely acknowledged to be dramatically under-utilised. Understanding the importance of pharmacovigilance and the mechanisms of national reporting systems is an essential but often neglected component of prescriber education.
The Scale of the Under-Reporting Problem
A landmark systematic review by Hazell and Shakir, examining reporting rates across multiple countries and drug classes, estimated that fewer than 6% of all serious ADRs are reported to national pharmacovigilance systems — and in some settings, as few as 1% [1]. The reasons for this profound under-reporting are well characterised:
- Ignorance — clinicians are unaware of reporting requirements or the relevant reporting mechanism
- Lethargy — the perceived effort of reporting outweighs the perceived benefit
- Diffidence — uncertainty about whether an observed event constitutes an ADR
- Complacency — the assumption that only safe drugs reach the market
- Indifference — scepticism about whether individual reports can influence drug safety decisions
The consequences of under-reporting are real and potentially catastrophic. Several drugs with serious, previously unrecognised adverse effects — including cardiovascular toxicity, serious skin reactions, and organ damage — have caused significant preventable harm before signals emerged from pharmacovigilance systems. Each delayed or missed report prolongs the period during which patients are exposed to uncharacterised risks.
How National Pharmacovigilance Systems Work
National pharmacovigilance reporting systems collect spontaneous ADR reports from healthcare professionals, patients, and pharmaceutical companies. These reports are aggregated and analysed using statistical methods to detect signals — unexpected patterns of association between a drug and an adverse event that exceed what would be expected by chance [2].
Signal detection uses techniques such as disproportionality analysis, comparing the observed reporting rate of a drug-event combination with the expected rate across the entire database. A signal does not confirm causation — it is a hypothesis-generating finding that triggers further investigation, which may include epidemiological studies, regulatory review, and ultimately product labelling updates or market withdrawal.
The World Health Organization coordinates a global pharmacovigilance network through its Programme for International Drug Monitoring, enabling the aggregation of ADR reports from member countries into a shared international database [2]. This global pooling is particularly important for detecting signals from rare but serious ADRs, which may not reach statistical significance in any single national dataset.
What Constitutes a Reportable Adverse Drug Reaction?
Clinicians should report any suspected ADR — defined as an unwanted or harmful reaction that occurs following the administration of a drug at normal doses. Crucially, a definite causal relationship is not required. Suspected reactions should be reported, including [1]:
- Any ADR to a newly authorised medicine
- Serious reactions to any established medicine (reactions causing hospitalisation, disability, congenital abnormality, or death)
- Any reaction resulting in pregnancy complications
- Unexpected reactions — events not described in the current product literature
- Reactions potentially caused by herbal or complementary medicines
The Value of Each Report
A common misconception is that individual reports carry little weight. In fact, a single well-documented case report of a serious unexpected adverse event can trigger a signal investigation that affects the safety profile of a drug used by millions of patients globally [2]. The case series that led to the identification of thalidomide embryopathy, the cardiac effects of domperidone, and the Stevens-Johnson syndrome risk with certain anticonvulsants all depended on clinician reporting.
Complete reports — including patient demographics, full drug history including doses and duration, chronological relationship between drug exposure and event, relevant investigations, and outcome — are far more valuable than brief notifications. The quality of the signal that can be extracted from pharmacovigilance databases is directly proportional to the quality and completeness of the individual reports submitted.
How MedNext Flags Safety Signals
MedNext Formulary incorporates safety alerts and adverse effect information from the MedNext Audited Proprietary Dataset, updated to reflect current post-marketing safety knowledge. Drug monographs include comprehensive adverse effect profiles organised by frequency — very common, common, uncommon, rare, and very rare — enabling clinicians to make informed prescribing decisions and counsel patients appropriately about what to monitor.
When you look up a drug in MedNext, the adverse effects section is not simply a list: it provides context about mechanism, reversibility, and clinical management of important reactions. This supports the clinical surveillance that underpins effective pharmacovigilance — if clinicians can more readily recognise potential ADRs, they are better positioned to report them.
References
- Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385-396.
- World Health Organization. The Importance of Pharmacovigilance: Safety Monitoring of Medicinal Products. Geneva: World Health Organization; 2002.